| P50 | author | Stanislas Lyonnet | Q7598948 |
| | Frank Lezoualc'h | Q40389426 |
| | Mélanie Métrich | Q40394406 |
| | Armelle Yart | Q58519521 |
| | Thomas Edouard | Q61053930 |
| P2093 | author name string | Maithé Tauber | |
| | Béatrice Parfait | |
| | Jean-Pierre Salles | |
| | Jean-Philippe Combier | |
| | Sophie Bel-Vialar | |
| | Audrey Nédélec | |
| | Francoise Conte-Auriol | |
| | Patrick Raynal | |
| P2860 | cites work | A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation | Q24318482 |
| | Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1 | Q24321087 |
| | Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair | Q24336157 |
| | Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease | Q24540529 |
| | A simplified system for generating recombinant adenoviruses | Q24682328 |
| | The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway | Q24799816 |
| | Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects | Q27314678 |
| | Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy | Q27865193 |
| | Germline gain-of-function mutations in SOS1 cause Noonan syndrome | Q28276979 |
| | PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects | Q28288812 |
| | Germline KRAS mutations cause Noonan syndrome | Q28297024 |
| | Stops along the RAS pathway in human genetic disease | Q28300658 |
| | Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy | Q28581098 |
| | Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor | Q28587239 |
| | Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation | Q28594140 |
| | The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 |
| | Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling | Q30477015 |
| | Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum | Q33637874 |
| | Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity | Q33962208 |
| | Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. | Q34099883 |
| | Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty | Q34307028 |
| | GSK3 takes centre stage more than 20 years after its discovery | Q34374129 |
| | Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling. | Q34421680 |
| | Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome | Q35879519 |
| | Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction | Q36599297 |
| | Glycogen synthase kinase-3beta -- actively inhibiting hypertrophy | Q36785340 |
| | Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways | Q36798027 |
| | Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis | Q36997611 |
| | Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome | Q36999895 |
| | Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development | Q37102143 |
| | Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation | Q37112471 |
| | Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation | Q38631424 |
| | Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. | Q39674852 |
| | Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis | Q39917153 |
| | Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibition | Q40048491 |
| | Glycogen synthase kinase 3beta inhibits myocardin-dependent transcription and hypertrophy induction through site-specific phosphorylation | Q40377590 |
| | Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation | Q40587895 |
| | Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies | Q41103757 |
| | Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome | Q42445553 |
| | Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes | Q42480603 |
| | Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment | Q42831428 |
| | Induction-independent recruitment of CREB-binding protein to the c-fos serum response element through interactions between the bromodomain and Elk-1. | Q42834097 |
| | Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors | Q46417560 |
| | cAMP-binding protein Epac induces cardiomyocyte hypertrophy. | Q46790567 |
| | Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. | Q52000174 |
| | The Adaptor Protein Gab1 Couples the Stimulation of Vascular Endothelial Growth Factor Receptor-2 to the Activation of Phosphoinositide 3-Kinase | Q64355677 |
| | The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinase | Q64377712 |
| | Bone morphogenetic proteins negatively control oligodendrocyte precursor specification in the chick spinal cord | Q78424874 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| | LEOPARD syndrome | Q1798016 |
| P304 | page(s) | 2498-507 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Molecular and Cellular Biology | Q3319478 |
| P1476 | title | Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling | |
| P478 | volume | 30 | |